{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tenofovir+Alafenamide+%28TAF%29&page=2", "query": { "intervention": "Tenofovir Alafenamide (TAF)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 142, "total_pages": 15, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tenofovir+Alafenamide+%28TAF%29&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tenofovir+Alafenamide+%28TAF%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T20:00:02.772Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03976752", "title": "Body Compartment Pharmacokinetics of Anti-retroviral Agents That May be Considered for Future On-demand Peri-exposure HIV Prophylaxis Regimens", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV/AIDS" ], "interventions": [ { "name": "Genvoya", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "MALE", "summary": "18 Years to 49 Years · Male only" }, "enrollment_count": 41, "start_date": "2019-03-13", "completion_date": "2019-09-20", "has_results": true, "last_update_posted_date": "2021-08-13", "last_synced_at": "2026-10-09T20:00:02.772Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03976752" }, { "nct_id": "NCT05005507", "title": "A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic Hepatitis B Virus Infection", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis B, Chronic" ], "interventions": [ { "name": "JNJ-73763989", "type": "DRUG" }, { "name": "PegIFN-alpha-2a", "type": "DRUG" }, { "name": "Tenofovir disoproxil", "type": "DRUG" }, { "name": "TAF", "type": "DRUG" }, { "name": "ETV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 1, "start_date": "2021-11-03", "completion_date": "2021-12-29", "has_results": true, "last_update_posted_date": "2024-03-06", "last_synced_at": "2026-10-09T20:00:02.772Z", "location_count": 1, "location_summary": "Hillsborough, New Jersey", "locations": [ { "city": "Hillsborough", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05005507" }, { "nct_id": "NCT04493216", "title": "A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "GSK3640254", "type": "DRUG" }, { "name": "ABC/3TC", "type": "DRUG" }, { "name": "FTC/TAF", "type": "DRUG" }, { "name": "Dolutegravir", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 161, "start_date": "2020-11-18", "completion_date": "2023-05-29", "has_results": true, "last_update_posted_date": "2024-06-26", "last_synced_at": "2026-10-09T20:00:02.772Z", "location_count": 9, "location_summary": "Los Angeles, California • Ft. Pierce, Florida • Orlando, Florida + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Ft. Pierce", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Berkley", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04493216" }, { "nct_id": "NCT03510468", "title": "Impact of Weekly Administration of Rifapentine and Isoniazid on Steady State Pharmacokinetics of Tenofovir Alafenamide in Healthy Volunteers (YODA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Tenofovir alafenamide", "type": "DRUG" }, { "name": "Rifapentine", "type": "DRUG" }, { "name": "Isoniazid (INH)", "type": "DRUG" }, { "name": "Pyridoxine", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 51, "start_date": "2018-06-12", "completion_date": "2022-12-21", "has_results": true, "last_update_posted_date": "2024-08-13", "last_synced_at": "2026-10-09T20:00:02.772Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03510468" }, { "nct_id": "NCT06005610", "title": "Estradiol Therapy In Transgender Women to Research Interactions With HIV Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV I Infection" ], "interventions": [ { "name": "Estradiol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 93, "start_date": "2024-01-04", "completion_date": "2025-08-21", "has_results": true, "last_update_posted_date": "2026-04-08", "last_synced_at": "2026-10-09T20:00:02.772Z", "location_count": 14, "location_summary": "San Diego, California • San Francisco, California • Aurora, Colorado + 11 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06005610" }, { "nct_id": "NCT07266831", "title": "A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Human Immunodeficiency Virus Type 1 (HIV-1) Infection" ], "interventions": [ { "name": "ISL", "type": "DRUG" }, { "name": "ULO", "type": "DRUG" }, { "name": "BIC/FTC/TAF", "type": "DRUG" }, { "name": "Placebo for BIC/FTC/TAF", "type": "DRUG" }, { "name": "Placebo to ISL/ULO", "type": "DRUG" }, { "name": "ISL/ULO", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 570, "start_date": "2025-12-18", "completion_date": "2031-12-18", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-09T20:00:02.772Z", "location_count": 24, "location_summary": "Los Angeles, California • Denver, Colorado • Washington D.C., District of Columbia + 20 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Ft. Pierce", "state": "Florida" }, { "city": "Miami Gardens", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07266831" }, { "nct_id": "NCT04039217", "title": "Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "ART", "HIV" ], "interventions": [ { "name": "Biktarvy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "MALE", "summary": "18 Years to 49 Years · Male only" }, "enrollment_count": 20, "start_date": "2019-09-30", "completion_date": "2020-08-28", "has_results": true, "last_update_posted_date": "2022-02-22", "last_synced_at": "2026-10-09T20:00:02.772Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04039217" }, { "nct_id": "NCT01818596", "title": "Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV", "HIV Infections" ], "interventions": [ { "name": "E/C/F/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 252, "start_date": "2013-03-27", "completion_date": "2018-07-18", "has_results": true, "last_update_posted_date": "2020-03-02", "last_synced_at": "2026-10-09T20:00:02.772Z", "location_count": 51, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 40 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Hayward", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01818596" }, { "nct_id": "NCT02469246", "title": "Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "F/TAF", "type": "DRUG" }, { "name": "ABC/3TC", "type": "DRUG" }, { "name": "ABC/3TC Placebo", "type": "DRUG" }, { "name": "F/TAF Placebo", "type": "DRUG" }, { "name": "3rd ARV agent", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 567, "start_date": "2015-06-29", "completion_date": "2019-03-13", "has_results": true, "last_update_posted_date": "2019-10-25", "last_synced_at": "2026-10-09T20:00:02.772Z", "location_count": 34, "location_summary": "Phoenix, Arizona • Beverly Hills, California • La Jolla, California + 26 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02469246" }, { "nct_id": "NCT07708727", "title": "Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "GS-3242 Tablet", "type": "DRUG" }, { "name": "GS-3242 Injection", "type": "DRUG" }, { "name": "Lenacapavir Tablet", "type": "DRUG" }, { "name": "Lenacapavir Injection", "type": "DRUG" }, { "name": "B/F/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 700, "start_date": "2026-07-29", "completion_date": "2033-04", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-10-09T20:00:02.772Z", "location_count": 9, "location_summary": "Florida City, Florida • Ft. Pierce, Florida • West Palm Beach, Florida + 5 more", "locations": [ { "city": "Florida City", "state": "Florida" }, { "city": "Ft. Pierce", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07708727" } ] }